We are currently in discussion with a number of individual and corporate advisors and afilliates who will significantly increase our bandwidth, competences and the reach of our networks. While each case is different all have agreed to the adittion of bios show below:

Mr Jeremy Curnock Cook

Mr Curnock Cook was formerly head of the life science private equity team at Rothschild Asset Management in the UK and an active investor in the Australian life science sector. At Rothschild, Mr Curnock Cook was responsible for the launch of the first dedicated biotechnology fund for the Australian market. Over his 40-year career, Mr Curnock Cook has specialised in creating value in emerging biotech enterprises, through active participation with management. He has served on over 40 boards in various roles, including chair of private and public biotechnology companies listed on NASDAQ, LSE, TSX and ASX. Mr Curnock Cook received his MA in Natural Sciences from Trinity College in Dublin, Ireland. He is currently Managing Director of Bioscience Managers, Chairperson of Avena Therapeutics and AmpliPhi Biosciences and sits on the board of Avita Medical, Rex Bionics Pty, Adherium Ltd and acts as an alternative Director to Sea Dragon Ltd. Mr Curnock Cook has held no other Australian public company directorships in the last three years.


Dr Katharina Schoenenberger


It is with profound sadness that we have learned of Dr Schoenenberger's recent death.  Our condolences to her friends, family and the many colleagues who have had the pleasure of working with her.

Dr Katharina Schoenenberger the managing partner of Schoenenberger + Partners SA. Initially headquartered in Rome it’s financial and M&A operations were subsequently moved to Lausanne and then to Lugano. Katharina’s training was in initially in medicine at the University of Zurich followed by economics and business administration at the Sapienza University of Rome. She is fluent in Italian, German, French and English and has accumulated a wealth of experience in finance and multinational deal-making in these languages.  Schoenenberger + Partners SA takes pride in a discrete personalized problem-solving approach to complex transactions and draws on a worldwide network in finance, business, life sciences, technology and public life to achieve results for clients.


Dr Mary Moran

Founder Policy Cures Consulting, Formerly Executive Director Policy Cures

MBBS (Bachelor of Medicine, Bachelor of Surgery, Hons); Grad Dip FAT (Foreign Affairs and Trade)

Dr Moran has over 20 years experience in health policy and practice, including 10 years specialising in neglected disease policy. She has conducted projects for a wide range of public and multilateral health organisations with a focus on policy solutions for emerging issues related to neglected disease R&D. In 2004, Mary founded the research group that became Policy Cures at the London School of Economics & Political Science, later transferring it to the George Institute for International Health in Sydney.


Greg Browne, CFO

Cyberonics, Inc.

Houston, TX, US


Medical Devices and Finance

Gregory H. Browne joined Cyberonics in July of 2007 as the Vice President, Finance and Chief Financial Officer.  He retired from LivaNation, the successor to Cyberonics in June 2016.  Mr. Browne has served as both Chief Executive Officer and Chief Financial Officer for several publicly traded healthcare companies. Most recently, from 2002 to 2006, he was Chief Financial Officer at Amedisys, Inc., a home nursing company with revenues in excess of $600 million, during a period of substantial growth in revenue, profitability and market capitalization. 


Ashley J. Stevens, D.Phil (Oxon),

President Focus IP Group, LLC and  Immediate Past Presiden Association of University Technology Managers

With over thirty years of leadership IP Group provides a variety of consulting services in intellectual property matters, including serving as an Expert Witness in intellectual property disputes, technology scouting, technology transfer and teaching the commercialization of early stage technologies.


Kathy Allen, CEO

AllenDay HR Consultancy

 London, UK


With over 25 years' HR consultancy experience. Kathy is a internationally recognised leader providing unrivaled HR talent management solutions in healthcare. Her experience spans Europe, the US and the Middle East.


Diane Mellett Chevrelles Consulting Ltd.

Diane  Mellett  has over 20 years experience as an advisor to the Biotech industry. She has  a legal background and has qualified as a lawyer in both the UK and the United States. After working in private practice she worked in house in Cambridge Uk for Cambridge Antibody Technology plc ( where she was General Counsel and a Board Director)  and then with  Astra Zeneca plc after if purchased CAT in 2007. She has for the past 6 years worked as independent consultant to a number of biotech  medical device and other intellectual property based  companies advising on strategic licensing agreements. patent strategies, asset sales and  major collaborations.